Introduction
============

The prevalence of chronic kidney disease (CKD) increases markedly with age,[@b1-cia-12-1049]--[@b3-cia-12-1049] with the highest prevalence observed among the oldest-old people, ie, those aged 80 years or older.[@b3-cia-12-1049],[@b4-cia-12-1049] The prevalence of cognitive decline including dementia also increases with age,[@b5-cia-12-1049] with an estimated prevalence of approximately 20% in individuals aged 80 years.[@b6-cia-12-1049] Both CKD and cognitive decline are major public health problems in aging populations and pose an enormous societal burden.[@b7-cia-12-1049]

As shown in several studies conducted in the past decade, kidney function is associated with cognitive decline.[@b8-cia-12-1049]--[@b11-cia-12-1049] However, to the best of our knowledge, no longitudinal study has investigated this association in an oldest-old Asian population.

Therefore, we prospectively investigated the association between kidney function and cognitive decline in an oldest-old Chinese population (≥80 years) with serum creatinine levels \<150 µmol/L.

Subjects and methods
====================

Subjects
--------

In 2004, 284 participants aged 80 years or older from Shandong, People's Republic of China, were recruited to participate in a double-blind placebo-controlled trial designed to establish the benefits and risks of antihypertensive treatment; this trial included an assessment of cognitive function.[@b12-cia-12-1049] All participants had hypertension (systolic pressure 160--200 mmHg; diastolic pressure \<110 mmHg), serum creatinine levels \<150 µmol/L, and no clinical diagnosis of dementia at baseline. Cognitive function was assessed with the Mini-Mental State Examination (MMSE) at both the baseline and annual visits. Participants were randomly assigned to receive antihypertensive treatment or placebo. After the trial ended in 2007, all participants received anti-hypertensive treatment and were followed for 1 year. Full details of the protocol have been published elsewhere.[@b13-cia-12-1049] In total, 247 participants (87.0%) provided valid MMSE data at their last visit. Written informed consent was obtained from all study participants, and the trial was approved by the ethics committee of Beijing Hypertension League Institute.

Evaluation of cognitive function
--------------------------------

All participants were assessed with the MMSE at baseline and annual visits. The MMSE is a brief standardized instrument that has been extensively used to assess individuals' cognitive function.[@b14-cia-12-1049] The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive function. The MMSE assesses attention, orientation, language, ability to follow simple verbal and written commands, and immediate and short-term recall. The scores were calculated by the coordinating office staff.[@b13-cia-12-1049]

According to previous studies, not all changes in the MMSE score reflect true clinical cognitive decline or improvement. Changes in MMSE test scores may also result from a practice effect, measurement error, regression to the mean, or normal aging.[@b15-cia-12-1049] The Reliable Change Index (RCI) is a statistical method that estimates the probability that the change in an individual's test scores is not due to chance. The RCI generated by Chelune et al[@b16-cia-12-1049] accounts for practice effects and measurement error, whereas Hsu[@b17-cia-12-1049] proposed an RCI that also accounts for regression to the mean. Both equations have been described in detail elsewhere.[@b16-cia-12-1049],[@b17-cia-12-1049] We calculated the RCI using both methods to improve the accuracy of the definition of cognitive decline. Based on a previous study of an elderly Chinese population, the test--retest reliability that we used for the calculation was 0.75.[@b18-cia-12-1049] A reliable decrease in the MMSE score was defined by an RCI of 1.645 (equivalent to a 90% confidence interval \[CI\]).

Evaluation of renal function at baseline
----------------------------------------

Baseline serum creatinine levels of all participants were measured by Jaffe's kinetic method using a Hitachi 7600 automated biochemical analyzer (Hitachi, Tokyo, Japan). The estimated glomerular filtration rate (eGFR) was calculated using the modified modification of diet in renal disease (MDRD) equation, which was developed using data from Chinese participants with CKD.[@b19-cia-12-1049] All participants had an eGFR \>30 mL/min/1.73 m^2^. Early-stage CKD was defined as an eGFR of 30--59 mL/min/1.73 m^2^.

Evaluation of covariates at baseline
------------------------------------

A detailed description of this procedure has been published elsewhere.[@b13-cia-12-1049] Baseline blood pressure measurements were collected from all participants. A questionnaire was used to obtain information on previous cardiovascular diseases (including myocardial infarction, atrial fibrillation, and stroke) and lifestyle behaviors. Body mass index was calculated as weight (kg) divided by height squared (m^2^). Hemoglobin, fasting glucose, uric acid, and total cholesterol levels were measured at baseline.

Statistical analysis
--------------------

Standard descriptive statistics were used to assess the baseline characteristics and to test for differences in the characteristics between participants with and without cognitive decline. Continuous variables were presented as mean ± SD or as the median (interquartile range \[IQR\]), and binary variables were presented as proportions. Data were compared using an independent *t*-test for continuous variables and *χ*^2^ test or Fisher's exact test for binary variables.

Poisson regression models were built to analyze the association between baseline kidney function and cognitive decline (presented as the relative risk \[RR\] and 95% CI). We first analyzed the eGFR as a binary variable: ≥60 (reference) and 30--59 mL/min/1.73 m^2^. Multivariate models were then constructed to adjust for potential confounding variables associated with kidney function and/or cognitive function, including age (continuous), gender (male vs female), body mass index (continuous), current smoking (no vs yes), previous cardiovascular disease (no vs yes), diastolic blood pressure (continuous), fasting blood glucose level (continuous), and total cholesterol level (continuous). Crude and adjusted RRs with 95% CIs are presented. We also used the same strategy to analyze eGFR with three categories: ≥60 mL/min/1.73 m^2^ (reference), 45--59 mL/min/1.73 m^2^, and 30--44 mL/min/1.73 m^2^.

We then analyzed the eGFR as a continuous variable (per 10 mL/min/1.73 m^2^ increase). A similar Poisson regression model was then generated. Moreover, as the accuracy of the eGFR calculated using equations to evaluate kidney function in the oldest old is controversial, we also used serum creatinine levels (continuous, per 0.1 mg/dL increase) to analyze the association using the same methods.

All *P*-values were two-tailed. Statistical tests were performed using SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results
=======

A total of 247 participants (87.0%) provided valid MMSE data at their last visit. The median and IQR of these participants' MMSE scores at baseline was 22 (20--23), and the change in MMSE score during follow-up was 2 (1--4). The distribution of responders and nonresponders was comparable in age (83.5±2.6 vs 83.3±2.7, *P*=0.76), gender (percentage of males 25.2% vs 32.4%, *P*=0.35), percentage with previous cardiovascular disease (5.3% vs 2.7%, *P*=1.0), and treatment group (53.7% vs 38.9%, *P*=0.23), but not the percentage of current smokers (6.1% vs 18.9%, *P*=0.01).

The baseline characteristics of the responders are shown in [Table 1](#t1-cia-12-1049){ref-type="table"}. The average age was 83.5±2.6 years, and 25.2% were male. Compared to subjects without cognitive decline, participants who developed cognitive decline were more likely to be male and had lower fasting blood glucose levels, higher diastolic blood pressure, higher serum creatinine levels, and a lower eGFR. The number of participants with eGFR ≥60 and 30--59 mL/min/1.73 m^2^ was 110 and 137, respectively.

A total of 18 (7.3%) cases of incident cognitive decline were observed during the follow-up period. In the crude analysis ([Table 2](#t2-cia-12-1049){ref-type="table"}), the RR of cognitive decline among participants with an eGFR of 30--59 mL/min/1.73 m^2^ was 4.01 (95% CI 1.16--13.87). After adjusting for potential confounding variables, including age, gender, body mass index, current smoking, previous cardiovascular disease, fasting blood glucose levels, diastolic blood pressure (baseline diastolic blood pressure was associated with incident dementia in a previous study[@b20-cia-12-1049]), and total cholesterol levels, multivariate-adjusted RR of cognitive decline among participants with an eGFR of 30--59 mL/min/1.73 m^2^ was 4.03 (95% CI 1.09--14.90).

When the eGFR was analyzed as a three-category variable ([Table 3](#t3-cia-12-1049){ref-type="table"}), the number of participants with eGFR ≥60, 45--59, and 30--44 mL/min/1.73 m^2^ was 110, 82, and 55, respectively. The multivariate-adjusted RR among participants with an eGFR of 45--59 and 30--44 mL/min/1.73 m^2^ was 2.75 (95% CI 0.65--11.67) and 7.29 (1.66--31.90), respectively.

When the eGFR was analyzed as a continuous variable ([Table 4](#t4-cia-12-1049){ref-type="table"}), the multivariate-adjusted RR for cognitive decline per 10 mL/min/1.73 m^2^ increase in eGFR was 0.68 (95% CI 0.47--0.97). When the serum creatinine level was used to evaluate kidney function, the multivariate-adjusted RR for cognitive decline per 0.1 mg/dL increase in serum creatinine level was 1.34 (95% CI 1.08--1.68).

Discussion
==========

In our previous study, which included a community-based population of 1,351 Chinese individuals \>40 years old with an eGFR of \>30 mL/min/1.73 m^2^, the odds ratio of developing cognitive decline was 2.73 (95% CI 1.00--7.56) among participants with an eGFR of 30--59 mL/min/1.73 m^2^ compared to those with an eGFR of \>90 mL/min/1.73 m^2^.[@b21-cia-12-1049] Based on the current prospective study, early-stage CKD (an eGFR of 30--59 mL/min/1.73 m^2^) was also associated with an increased risk of cognitive decline in an oldest-old Chinese population; this association was independent of age, gender, and other confounders. Given the high prevalence of early-stage CKD in the oldest old,[@b4-cia-12-1049] CKD poses substantial risk as a contributing factor to cognitive decline.

The association between CKD and cognitive function has been recognized in recent decades. According to several cross-sectional and longitudinal studies, CKD is associated with an increased risk of cognitive decline in adults. In a study by Kurella et al,[@b22-cia-12-1049] CKD was associated with an increased risk of cognitive impairment in the elderly, and this risk could not be fully explained by other well-established risk factors; furthermore, more advanced stages of CKD were found to be associated with an increased risk of cognitive impairment. Khatri et al[@b23-cia-12-1049] reported an association between decreased kidney function and cognitive decline in individuals with even mild CKD. In addition, Buchman et al[@b8-cia-12-1049] observed an association between impaired kidney function and a more rapid rate of cognitive decline in the elderly. However, Slinin et al[@b24-cia-12-1049] did not observe an independent association of mild-to-moderate reductions in kidney function with increased global cognitive impairment or risk of cognitive decline in older men. In addition, Helmer et al[@b9-cia-12-1049] did not observe an association between increased risk of cognitive decline or dementia and low eGFR values, but a faster decrease in eGFR and proteinuria were associated with global cognitive decline and incident dementia with a vascular component. A more plausible explanation is that a rapid decrease in eGFR and proteinuria reflect more severe kidney damage or dysfunction, whereas a low eGFR alone is common during aging in the absence of a true pathologic process; these explanations should be verified in further investigations.

Several mechanisms may explain the association between kidney function and cognitive decline. Small vessel disease in the brain and kidney is considered to be a key contributor to this relationship.[@b25-cia-12-1049] Hemodynamic similarities in vascular beds between the brain and the kidney have been observed.[@b25-cia-12-1049] In addition, both the brain and kidney are low-resistance end organs that are exposed to a high volume of blood flow throughout the cardiac cycle.[@b25-cia-12-1049] The exposure of small vessels to high flow and high pulsatile pressure may explain the presence of microvascular damage resulting in cognitive function deterioration and renal insufficiency.[@b26-cia-12-1049] The brain and kidney also share common cardiovascular risk factors, such as hypertension, hypercholesterolemia, diabetes mellitus, and smoking, which entail pathological microvascular changes mediated by oxidative and inflammatory processes occurring in similar endothelial structures and low-resistance vascular beds.[@b27-cia-12-1049] Impaired endothelial function is manifested as susceptibility to white matter changes, lacunar infarcts, microinfarcts, and defects in the blood--brain barrier in the brain and as impaired glomerular filtration and secondary proteinuria in the kidney.[@b27-cia-12-1049] Moreover, anemia[@b28-cia-12-1049] and hyperhomocysteinemia[@b29-cia-12-1049] are common even in early-stage CKD and have been suggested to be correlated with incident dementia.

Our study has several limitations. First, we did not include a large number of participants, and the median follow-up period of 3.3 years for repeated cognitive function tests was comparatively short. Both of these limitations resulted in a relatively small number of cases of incident cognitive decline, and this small sample size limited the statistical power of the analyses. Second, we lacked information on the participants' educational background, which is significantly associated with cognitive function. However, the median MMSE score of all participants was 22, which was relatively low, and the IQR of the MMSE score was 20--23, which was relatively narrow. These low scores might have occurred because all participants were recruited from the same region and were aged 80 years or older; we speculate that all participants might have had a similar and relatively insufficient level of education. Third, an optimal method for estimating kidney function among the oldest old has not been clearly established. We used both the eGFR and serum creatinine levels to evaluate kidney function, and the results were consistent, suggesting that the findings presented in this study were robust. Fourth, we used MMSE scores to define cognitive decline instead of a gold standard method involving a psychiatrist-obtained history and interactions with the family and a caregiver. Fifth, albuminuria may be correlated with cognitive decline. However, information regarding the participants' urinalysis was missing. Finally, as our study was observational, residual confounders of some unmeasured covariates may exist.

Despite these limitations, our study had several strengths. First, we explored the relationship between kidney function and cognitive decline in an oldest-old population, and this relationship has only been investigated in a few studies. Second, we calculated the RCI using two methods simultaneously to exclude a practice effect, measurement error, and regression to the mean, and this approach improved the accuracy of the definition of cognitive decline. Third, we used improved statistical methods compared to those applied in previous studies. To analyze the associations, we generated Poisson regression models, which are more suitable when the probability of the outcome is low.[@b30-cia-12-1049] We also used the Poisson regression models to estimate RR, which is preferred over the odds ratio in most prospective investigations.

Conclusion
==========

Our prospective study suggests that early-stage CKD is associated with cognitive decline in an oldest-old Chinese population. These findings may help clinicians identify individuals at a high risk of developing cognitive decline, and strategies to prevent or delay the incidence of cognitive decline in the oldest old should thus be targeted in further research.
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###### 

Baseline characteristics of the participants according to cognitive decline status

  Variables                            All participants   Participants without cognitive decline   Participants with cognitive decline   *P*-value
  ------------------------------------ ------------------ ---------------------------------------- ------------------------------------- -----------
  Number of participants               247                229                                      18                                    
  Male, %                              25.2               23.7                                     44.4                                  0.09
  Age, years                           83.5±2.6           83.5±2.7                                 82.9±2.2                              0.36
  Current smoking, %                   6.1                5.7                                      11.1                                  0.30
  Previous cardiovascular disease, %   5.3                5.2                                      5.6                                   1.00
  Treatment group, %                   52.6               53.7                                     38.9                                  0.23
  Body mass index                      23.8±14.2          23.9±14.7                                22.6±1.6                              0.25
  Hemoglobin, g/dL                     12.2±1.4           12.2±1.4                                 11.9±1.6                              0.49
  Fasting blood glucose, mmol/L        5.0±0.8            5.0±0.8                                  4.6±0.6                               0.05
  Total cholesterol, mmol/L            4.6±0.8            4.6±0.8                                  4.6±0.6                               0.87
  Serum uric acid, µmol/L              258.8±78.8         257.0±77.9                               282.4±88.2                            0.19
  Systolic BP, mmHg                    176.4±13.1         176.5±13.2                               178.0±11.3                            0.64
  Diastolic BP, mmHg                   84.3±9.9           83.9±9.9                                 89.8±7.4                              0.01
  Serum creatinine, µmol/L             100.0±23.9         98.6±23.5                                118.5±21.7                            0.001
  eGFR, mL/min/1.73 m^2^               62.6±22.1          63.5±22.2                                51.9±18.7                             0.03
  Categories of eGFR, %                                                                                                                  
    ≥60 mL/min/1.73 m^2^               44.5               46.7                                     16.7                                  0.01
   30--59 mL/min/1.73 m^2^             55.5               53.3                                     83.3                                  0.01
  Median MMSE score (IQR)              22 (20--23)        21 (20--23)                              25 (23--29)                           \<0.001

**Note:** Data are presented as percentages or mean ± SD unless indicated otherwise.

**Abbreviations:** BP, blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; MMSE, Mini-Mental State Examination.

###### 

Kidney function and cognitive decline

  eGFR and cognitive decline                                             eGFR ≥60 (n=110)   eGFR 30--59 (n=137)
  ---------------------------------------------------------------------- ------------------ ---------------------
  Crude RR                                                               Reference          4.01 (1.16--13.87)
  Age, gender-adjusted RR                                                Reference          5.16 (1.46--18.25)
  Multivariable-adjusted RR[a](#tfn4-cia-12-1049){ref-type="table-fn"}   Reference          4.03 (1.09--14.90)

**Notes:** Data are presented as RR (95% CI).

The model was further adjusted for body mass index, current smoking status, previous cardiovascular disease, fasting blood glucose level, diastolic BP, total cholesterol level, and treatment group.

**Abbreviations:** BP, blood pressure; eGFR, estimated glomerular filtration rate (mL/min/1.73 m^2^); RR, relative risk.

###### 

eGFR and cognitive decline

  eGFR and cognitive decline                                             eGFR ≥60 (n=110)   eGFR 45--59 (n=82)   eGFR 30--44 (n=55)
  ---------------------------------------------------------------------- ------------------ -------------------- --------------------
  Crude RR                                                               Reference          3.13 (0.81--12.10)   5.33 (1.41--20.10)
  Age, gender-adjusted RR                                                Reference          3.82 (0.97--15.00)   7.91 (2.01--31.10)
  Multivariable-adjusted RR[a](#tfn7-cia-12-1049){ref-type="table-fn"}   Reference          2.75 (0.65--11.67)   7.29 (1.66--31.90)

**Notes:** Data are presented as RR (95% CI).

The model was further adjusted for body mass index, current smoking status, previous cardiovascular disease, fasting blood glucose level, diastolic BP, total cholesterol level, and treatment group.

**Abbreviations:** BP, blood pressure; eGFR, estimated glomerular filtration rate (mL/min/1.73 m^2^); RR, relative risk.

###### 

eGFR, serum creatinine, and cognitive decline

                                                                          eGFR, per 10 mL/min/1.73 m^2^ increase   Serum creatinine per 0.1 mg/dL increase
  ----------------------------------------------------------------------- ---------------------------------------- -----------------------------------------
  Crude RR                                                                0.72 (0.52--0.99)                        1.37 (1.12--1.67)
  Age, gender-adjusted RR                                                 0.65 (0.45--0.92)                        1.34 (1.10--1.62)
  Multivariable-adjusted RR[a](#tfn10-cia-12-1049){ref-type="table-fn"}   0.68 (0.47--0.97)                        1.34 (1.08--1.68)

**Notes:** Data are presented as RR (95% CI).

The model was further adjusted for body mass index, current smoking status, previous cardiovascular disease, fasting blood glucose level, diastolic BP, total cholesterol level, and treatment group.

**Abbreviations:** BP, blood pressure; eGFR, estimated glomerular filtration rate (mL/min/1.73 m^2^); RR, relative risk.
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